ESR, complement, important indicators of systemic lupus erythematosus activity!
Challenge AstraZeneca's first new category of complement drug Aspaveli in more than ten years to obtain approval!
AstraZeneca's new indications for major complement C5 inhibitors receive FDA priority review qualification
First in class oral complement C5aR inhibitor approved in Japan
Novartis's first complement factor B inhibitor iptacopan has been certified by the British Innovation Passport
Novartis' potential "first-in-class" complement inhibitor reaches phase 2 clinical endpoint
Phase 3 clinical results of C3 complement inhibitors for the treatment of age-related macular degeneration released
Express U.S. FDA approves the first oral complement 5a receptor inhibitor
Oral complement C5a receptor inhibitor approved in Japan
, and the advantages of multiple disciplines complement each other to overcome diagnostic problems!
agents and traditional treatment methods complement each other
Front Immunol: In SARS-CoV-2 infection, excessive activation and consumption of complement can increase hospital mortality!
Single-base editing company Beam and Apellis collaborate to develop gene editing therapies for complement diseases
Express delivery effect lasted for 52 weeks, and long-acting complement inhibitor reached the primary phase 3 clinical endpoint
Join forces to develop base editing therapy to treat complement-mediated diseases
Efficacy lasts for 52 weeks and long-acting complement inhibitors reach the primary phase 3 clinical endpoint
JNNP-phosphorylated tau and neurofilament light chain protein can complement each other's strengths and predict cognitive ability
Innovent announces the world's first ophthalmic anti-VEGF-complement dual target drug IBI302
The 10 billion complement inhibitor market "triples", Alexion's exclusive position was broken; Novartis, Sanofi...
Target the root cause of complement diseases!